摘要
B7⁃H3也被称为CD276,是近年来发现的新的免疫检查点,属于B7超家族。其在人类的正常组织中低表达或者不表达,然而在免疫细胞和肿瘤组织中异常表达。B7⁃H3与肿瘤的免疫治疗相关,在肿瘤微环境(tumor microenvironment,TME)中发挥着共刺激/共抑制的双重作用。因而,以B7⁃H3为靶点能够实现肿瘤免疫治疗的精准定位,从而增强抗肿瘤的免疫反应。本文主要综述了B7⁃H3的结构与功能、其在肿瘤免疫中的生理作用以及靶向治疗方法的研究进展。虽然B7⁃H3在肿瘤方面的免疫功能已经被广泛揭示,而且开发的靶向药物也进入了临床前和临床试验。但是B7⁃H3在人体内的不同存在形式及功能仍有所争议,人源结构始终未能得到解析,其潜在的受体也尚未得到确认。所以有必要进一步探讨B7⁃H3在肿瘤免疫治疗方面的确切证据以及现有治疗方法的挑战性和局限性,旨在为靶向B7⁃H3的药物开发提供新的方向和途径。
B7⁃H3,also known as CD276,is a new immune checkpoint discovered in recent years and belongs to the B7 superfamily.It has low or no expression in normal human tissues,but abnormal expression in immune cells and tumor tissues.B7⁃H3 is related to tumor immunotherapy and plays a dual role of co⁃stimulation/co⁃inhibition in tumor microenvironment(TME).Therefore,targeting B7⁃H3 can achieve accurate tumor immunotherapy,thus enhancing anti⁃tumor immune responses.As the immune function of B7⁃H3 in tumors has been widely revealed,targeted drugs have also been developed and have entered preclinical and clinical trials.However,the different forms and functions of B7⁃H3 in human body are still controversial,the human origin structure has not been analyzed,and its potential receptor has not been confirmed.In this paper,the structure and function of B7⁃H3,its physiological role in tumor immunity and the research progress of targeted therapy are reviewed.In the future,it is necessary to further explore the exact evidence of B7⁃H3 in tumor immunotherapy and the challenges and limitations of exist⁃ing therapies,in order to provide new directions and approaches for drug development targeting B7⁃H3.
作者
陈佳玥
王丰
CHEN Jia-Yue;WANG Feng(School of Life Science,Beijing Institute of Technology,Beijing 100081,China)
出处
《中国生物化学与分子生物学报》
北大核心
2025年第7期933-946,共14页
Chinese Journal of Biochemistry and Molecular Biology
基金
国家重点研发计划—精准医学研究项目(No.2016YFC0906002)资助。
关键词
免疫检查点B7-H3
肿瘤微环境
靶向治疗
药物开发
immune checkpoint B7⁃H3
tumor microenvironment(TME)
targeted therapy
drug development
